GSK relaunches COPD patient site with blockbuster sales on the line

GlaxoSmithKline's ($GSK) new respiratory blockbuster hopefuls, Anoro and Breo, aren't quite where analysts thought they'd be by now. And with the pair slated to take the torch from aging giant Advair, Glaxo is taking their marketing seriously. As part of that effort, the British pharma has relaunched its, a patient education and disease management site where COPD sufferers "are invited to take steps to strengthen their relationships with healthcare providers" and "work closely with their physician to develop an individualized COPD action plan," the company said. Release | More